Given that IFN therapy administered to COVID‐19 patients shortly after onset of symptoms prevented disease progression to severe stages, shortened hospital stays, and reduced viral load, we expect early‐stage use of the ES‐Biofactory➔IFN‐β will prompt a similarly effective response. This evidence concerns the gene IFNA1 and COVID-19.